Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2101
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Parenteral, Intravenous
01
Overview
TQB2101 is an **antibody-drug conjugate (ADC)** targeting **receptor tyrosine kinase-like orphan receptor 1 (ROR1)**, a transmembrane protein in the type I receptor tyrosine kinase family. ROR1 is minimally expressed in normal adult tissues but highly expressed in a variety of malignancies, including hematological cancers, lung cancer, pancreatic cancer, breast cancer, colorectal cancer, and ovarian cancer. TQB2101 is designed to selectively bind to ROR1-positive tumors, delivering a cytotoxic payload directly to malignant cells while sparing normal tissues. Preclinical data showed anti-tumor activity in multiple ROR1-positive tumor models with a favorable safety profile. The drug is being developed for the treatment of advanced malignant tumors and is currently in early-phase clinical trials in China[1][3][5][7][9].
- Brand names
- TQB2101TQB-2101TQB 2101
- Other names
- TQB2101TQB-2101TQB 2101
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on TQB2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2101.